Abstract
Stem cells and haematopoiesis
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Wnt signalling

Wnt signalling is one of the most well studied molecular pathways regulating stem cell self-renewal and proliferation. There are two major categories of Wnt signalling: the canonical pathway in which a cytoplasmic protein ␤-catenin is a key mediator, and the ␤-catenin independent, non-canonical pathway. Canonical Wnt signals are vitally involved in cell fate determination, whereas noncanonical signals are essential for control of cell movement and tissue polarity [43]. In the canonical Wnt pathway, signalling is initiated by the binding of Wnt ligands to a receptor complex comprising a receptor of the Frizzled family and a co-receptor, Lrp5/6, that belongs to the low-density lipoprotein receptor family [44]. In the absence of Wnt signalling, ␤-catenin binds to axin, adenomatous polyyposis coli and glycogen synthase kinase 3␤. The resulting complex is then phosphorylated and degraded, which keeps
␤-catenin at a low level [45, 46] [50] . [53] . Wnt signalling may also be involved in lymphoid leukaemia. For instance, Wnt16 was initially cloned due to over-expression in pre-B-cell leukaemia lines having E2A-PbX translocation, suggesting an oncogenesis model involving autocrine Wnt usage [53] . Recently loss of ␤-catenin was shown to impair the self-renewal capacity of both normal and CML stem cells in vivo [54] [55] . The pathway is initiated when Notch ligands bind to the epidermal growth factor (EGF)-like receptors Notch1-4, and signalling is processed by the enzyme ␥-secretase [56, 57] . An in vitro mouse model has shown that Notch signalling is highly active in HSC and is down-regulated as differentiation proceeds [58] . However, inhibition of the pathway significantly accelerates cell differentiation [58] . This suggests a crucial role for the Notch pathway in the maintenance of HSC capable of self-renewal in an undifferentiated state. Importantly, identified target genes of the Notch pathway include some well studied proto-oncogenes and cell cycle regulators, including myc, Cdkn1a and cyclinD1 [57] . Dysregulation of the Notch pathway is implicated in various malignancies such as breast cancer, medulloblastoma, colorectal cancer, pancreatic cancer and leukaemia [59, 60] . In leukaemia, a causative role of the Notch1 protein (N1ICD) in disease induction was first described when it was found that overexpression of N1ICD led to immature T-cell neoplasm in mice [57] . Subsequent studies went further to show a link between N1ICD dysfunction and various other lymphomas, like anaplastic large cell lymphoma [61] , in which oncogenesis is due to an important role for the N1ICD in HSC self-renewal [62, 63] [64] . In HSC and haematopoietic progenitors derived from umbilical cord blood, NF-B regulatory proteins and transcription factors for genes like tumour necrosis factor (Tnf), fibroblast growth factor (Fgf) and Notch1 are overexpressed [55] . [66, 67] .
Dysregulation of Wnt signalling is critical to the initiation of epithelial carcinomas like colon cancer [51, 52]. Here, emphasis is given to its emerging role in leukaemia. The AML-associated translocation products AML1-ETO, promyelocytic leukaemia retinoic acid receptor-␣ (PML-RAR␣) and promyelocytic zinc finger protein (PLZF-RAR␣) are associated with Wnt signalling [53]. A co-activator of Wnt Tcf and Lef transcription factors is plakoglobin, whose presence in leukaemia positively regulates the production of all three fusion proteins mentioned, inducing expression of ␤-catenin and hence enhancing the replating capacity of leukemic cells in vitro
Notch and NF-B signalling
The Notch pathway is another signal transduction pathway that functions as a major regulator of cell fate in the haematopoietic system. It is also thought to interact with NF-B pathway during this process. Similar to Wnt genes, Notch genes encode evolutionarily conserved transmembrane bound receptors and signalling is mediated via cell-to-cell contact
. In addition, recent studies suggest that Notch3 may be a co-contributor in regulating the self-renewal mechanism of early T-cell precursors [57], and thus the development of T-cell leukaemia. However, direct evidence illustrating the cellular targets of Notch-related malignant transformations is rare. This finding indicates an essential role for the Notch pathway in the self-renewal of cancer stem cells. NF-B signalling is involved in many cellular processes including response to immune or inflammatory stimuli, cell growth and apoptosis
The pivotal role of NF-B in the control of apoptosis [42] links this transcription factor to the development of haematopoietic cancers. Dysfunction of NF-B is observed in multiple myeloma, chronic lymphocytic leukaemia and several other lymphomas, in which the NF-B gene is constantly activated [65]. Manipulation of the NF-B pathway could be used to drive stem cells to a desired fate. There has been increasing evidence to show that Notch and NF-B interact with each other in disease pathogenesis. A direct link between Notch and NF-B was provided by a recent study using N1ICD to induce the activity of NF-B reporters. In this study, Aifantis and colleagues [66] identified NF-B as one of the major mediators of Notch1-induced transformation. They reported that constitutively active Notch1 mediates the NF-B pathway transcriptionally via the IB kinase complex, which consequently results in the expression of several well characterized target genes of NF-B in HSC
Hedgehog signalling and Bmi1
The Hh pathway, in which Bmi1is a key regulator, also plays a crucial role in stem cell self-renewal and cancer cell proliferation. Hh is a known cell cycle regulator of HSC. Under homeostatic conditions, activation of the Hh pathway induces cell cycling and expands the pool of stem cells in bone marrow [68, 69] . However, Hh activation modulates specific cell cycle regulators, such as CyclinD1, which can result in HSC exhaustion [69] such that HSC lose their ability to regenerate haematopoiesis upon secondary engraftments [69] . The proliferation of primitive haematopoietic cells induced by Hh activation is thought to involve BMPs [69] . In particular, cytokine-induced proliferation of HSC can be inhibited by antibodies to Hh, and a similar effect can be obtained using an inhibitor of BMP4 [68] . Furthermore, studies based on multiple myeloma, a plasma cell malignancy of the bone marrow, suggest that Hh activation is heterogeneous across the spectrum of multiple myeloma stem cells and their more differentiated progeny [68] . For HSC, Polycomb group genes have been shown to play a key role in preventing premature senescence, and hence prolong the life span of the stem cell [70] . Recent studies have shown that Bmi1 is a key regulator in this process. For example, Bmi-1 determines the proliferative capacity of normal and leukemic stem cells [71, 72] . There has been evidence to suggest that Bmi1 regulates stem cell self-renewal by modulating genes in the Shh pathway, one of three homologous Hh pathways, As a gene downstream of Shh, it regulates proliferation, survival and lineage commitment [73, 74] . In this process, Bmi1 affects the activities of p53 and CDK4/CDK6 cyclin-dependent kinases by repressing two corresponding tumour suppressors, p16
Ink4a and p19 Arf [70] . Bmi1 is highly expressed in purified HSC and its expression declines as differentiation progresses. Conversely, inactivation of Bmi1 in the mouse leads to a decrease in the number of haematopoietic cells and impaired proliferative response of these cells to mitogens [75] . Also, it has been shown that Bmi1 is implicated in selfrenewal of neural stem cells [76] , although not for neural progenitor proliferation [77] . 
Concluding remarks: cancer stem cells as a target for new cancer therapy
